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Nipple aspirate fluid: a promising non-invasive method
to identify cellular markers of breast cancer risk
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Summary To evaluate the feasibility of nipple aspiration and to identify intermediate markers of breast cancer risk, nipple aspirate fluid (NAF)
was collected from 177 subjects using a modified breast pump. The first 33 subjects demonstrated that we could obtain NAF quickly, reliably
and repeatedly. Specimens from the remaining 144 subjects were collected to evaluate promising cellular biomarkers. NAF was obtained in
167 out of 177 (94%) subjects overall and in 99% of the 144 most recent subjects. Sufficient NAF was obtained to evaluate cytology in 160
out of 167 (96%) cases and specimens were sufficiently cellular to analyse DNA markers in 53% of cases. Among the last 144 subjects,
menopausal status did not influence the ability to obtain NAF. NAF cytology correlated with increased breast cancer risk (P = 0.002). Using
computerized image analysis of NAF epithelial cells, DNA index (P = 0.0002), percentage of cells in G2M (P= 0.05) and percentage of cells
with hypertetraploidy (P= 0.002) increased as cytology became more abnormal. Our data indicate that NAF can be obtained in essentially all
eligible subjects; that breast epithelial cells are evaluable in > 95% of NAF samples for cytology and in over half of NAF samples for DNA
index (ploidy) and cell cycle analysis; and that abnormal NAF cytology correlates with increased breast cancer risk. This suggests that
biomarkers identified in nipple aspirate fluid may prove useful either as an adjunct to currently accepted breast cancer screening methods, or
to evaluate response to a chemopreventive agent.
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Despite the death of 45 000 women annually in the United States
from the disease, the ability to assess a woman's riskofdeveloping
breast cancer remains inadequate. The only well-established
procedures to screen subjects for breast cancer are physical exam-
ination and mammography. Unfortunately, physical examination
does not identify a significant number ofearly breast cancers and
mammograms miss 10-40% of early breast cancers (Giuliano,
1994). Additional screening tools to identify precancer and early
breast cancer are urgently needed.
Although the early detection of breast cancer will lead to a
higher cure rate, the ideal form of treatment is prevention. The
prevention of breast cancer is hindered by the difficulty in identi-
fying an effective agent. Effective agents are difficult to identify in
part because of the long period required for breast cancer to
develop and, consequently, the requirement for lengthy clinical
trials to test the efficacy ofthe agent, ifthe end point is the preven-
tion of cancer. One way to shorten the time to finding of an effec-
tive agent is the identification of intermediate biomarkers, which
are biological alterations in cells or tissue that occur between the
time of initiation and tumour invasion. The theory is that an agent
that partially or completely reverses the intermediate biomarker
back to a normal phenotype may be interrupting carcinogenesis.
Validation of the biomarker would require that the agent also
decrease the incidence ofcancer. Evaluating the effect ofthe agent
requires the analysis of tissue, cells or non-cellular fluid. Nipple
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aspiration, which is simple, quick, reliable and repeatable, would
be an excellent tool to evaluate the efflcacy of a chemopreventive
agent should intermediate biomarkers be identified in the fluid.
Presentefforts to evaluatethebreastdirectly, through evaluation
ofeither tissue or individual cells, have been hindered because the
analysis of these specimens generally requires an invasive proce-
dure. The adult non-pregnant, non-lactating breast secretes fluid
into the breast ductal system. This fluid can be obtained through
aspiration ofthe nipple with a modified breast pump. Refinements
in the ability to obtain this fluid, as well as epidemiological studies
to identify subjects most likely to yield NAF, have been on-going
for over 20 years. Nipple aspiration has the attractiveness of
quickly, painlessly, and non-invasively obtaining breast epithelial
cells, the cells at risk for transformation to breast cancer.
Nonetheless, limitations in the ability to obtain NAF in 30-50% of
subjects has hindered the development of the technique as a tool
for both breast cancer screening and evaluating response to treat-
ment (Petrakis, 1993).
Ourstudy had two goals. The first was to determine ifthe proce-
dure was feasible. Thatis, could NAF be obtained consistently and
were the NAF samples sufficiently cellular such that accepted
markers ofprognosis in breast tumours (e.g. cytology and ploidy)
could be evaluated in the fluid? Ifitcouldbe demonstrated thatthe
procedure was feasible, the next goal was to identify intermediate
biomarkers in the NAF that would correlate with breast cancer
risk. Subjects of all risk categories were recruited. Cytological
study ofthe Papanicolaou-stained smears and computerized image
analysis were used to identify promising cellular markers of
breast cancer risk. We evaluated markers such as cellular atypia,
DNA index or ploidy and S-phase fraction, which in breast carci-
noma tissue specimens are known to correlate with prognosis
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(Leis, 1991). We hypothesized that higher levels ofthese markers
in NAF epithelial cells would correlate with increasing breast
cancer risk. Because ofa previous report indicating that NAF was
more successful in premenopausal subjects, we also evaluated the
influence of menopausal status on our ability to obtain NAF. Our
findings form the basis ofthis report.
MATERIALS AND METHODS
Subjects
One hundred and seventy-seven non-Asian subjects aged 30-65
years (women undergoing mastectomy excepted) were recruited
between August 1994 and June 1996 after approval of the Fox
Chase Institutional Review Board. Asians, as well as women
under 30 or greater than 65 years, were excluded because the
success in obtaining NAF from the intact breast in these groups is
known to be low (Petrakis, 1993). These subjects werecategorized
by their risk for breast cancer as having no risk factors, a first-
degree relative with breast cancer, a history of curative treatment
for ductal carcinoma in situ (DCIS) or invasive breast cancer,
precancerous mastopathy [atypical hyperplasia (AH) or lobular
carcinoma in situ (LCIS) or recently diagnosed DCIS] or recently
diagnosed invasive cancer of the breast. We relaxed the age limit
for women undergoing mastectomy to include subjects up to 72
years old because: (1) there are no data outlining the NAF yield
from a breast that has just been removed and (2) our preliminary
attempts to obtain NAF in mastectomy specimens from women up
to 72 years of age were successful. Aspiration visits spaced either
3 days apart (subjects undergoing 6-12 aspirations) or 2 weeks
apart (subjects undergoing two or three aspirations) were
performed by a trained physician or nurse clinician.
Aspiration technique
After informed consent was obtained, nipple fluid was aspirated
using a modified breast pump. The device consists of a 10-ml
syringe attached to the endofa no. 4 endotracheal tube overwhich
is placed arespiratory humidification adaptor. Each ofthese pieces
is inexpensive andreadily available in any hospital where mechan-
ical respiratory support is provided.
For subjects in whom the intact breast was aspirated, the indi-
vidual was seated in a comfortable position and the breast nipple
cleansed with alcohol. Afterthe alcohol evaporated, a warm, moist
cloth was placed on each breast. After 1-2 min, the cloths were
removed, the patient massaged her breast with both hands, and the
plunger of the syringe was withdrawn to the 7-ml level and held
for 15 s or until the patient experienced discomfort. A similar
degree of suction was created with the syringe in mastectomy
specimens obtained immediately after surgical excision. Fluid in
the form ofdroplets was collected in capillary tubes. The quantity
of fluid varied from 1 pl to 200 p1. The negative pressure
produced was well tolerated. The procedure was repeated once on
the same breast. Aspiration was then performed on the opposite
breast, if present. If there was insufficient fluid from either breast
to collect into one or more capillary tubes, orifthe only breast that
could be sampled (because of previous mastectomy) yielded no
collected fluid, the patient was designated a non-secretor.
Occasionally, keratin plugs rather than NAF were obtained after
suction was completed. The plugs were removed with an alcohol
swab and suctioning repeated. Occasionally, suctioning was
performed two or three times to remove all ofthe plugs. Fluid was
then obtained frequently. In order to obtain additional fluid, the
nipple was gently compressed by the subject between her fingers.
One or two additional droplets offluid often appeared.
Cytology
Specimenpreparation
The NAF was collected in 50-p1 capillary tubes, rinsed into a
container with 1 ml of 2% polyethylene glycol in ethanol-
isopropanol and transported to the cytology laboratory for
processing. In subjects with normal breast cancer risk, a family
history ofbreast cancer, AH, or LCIS the samples were combined,
given that the risk ofinvasive breast cancer is approximately equal
in each breast. To evaluate the validity of this approach, early in
our experience we collected NAF from nine subjects with AH or
LCIS. The fluid from each breast was placed in separate
containers. In seven out ofnine cases, the cytology in both breasts
was the same. In one ofthe remaining subjects, the abnormal NAF
cytology was found in the breast opposite to where a prior biopsy
had demonstrated AH, whereas in the second case the abnormal
cytology was in the ipsilateral breast. If a cytology report was
available from each breast, the report from the breast at highest
risk was recorded. If a cytology report was available from each
breast and the breasts were at equal risk, either the left or the right
breast sample was selected randomly. If multiple cytological
samples were analysed from the same breast, the most abnormal
result was used in our analyses.
On the other hand, for subjects with previously treated DCIS or
invasive breast cancer, only the breast without prior disease was
aspirated. This was because the breast with disease had already
been removed orradiated. For subjects with recently diagnosed but
not yetdefinitively treated DCIS orinvasive breastcancer, only the
breast diagn6sed with in situ or invasive disease was aspirated.
Table 1 Cytological criteria for nipple aspirate specimens
Scant mammaryepithelial cells
This includes acellular specimens, those with only foam cells or with fewer
than ten mammary epithelial cells
Benign mammary epithelialcells
This consists of specimens containing more than ten mammary epithelial
cells without cytological atypia. This category encompasses normal
mammary cells, apocrine metaplasia, and duct hyperplasia without atypia.
We subdivide this category into:
(a) Normal/non-papillary - single cells or small, loosely cohesive
aggregates of cells.
(b) Hyperplastic - large three-dimensional clusters of cells (indicative of
duct hyperplasia or papillomatosis)
Atypical mammary epithelialcells
This category consists of specimens with ten or more mammary epithelial
cells that exhibit atypical features. Atypia is defined as nuclear enlargement
and/or irregularity, increased nuclear to cytoplasmic ratio or a chromatin
distribution abnormality short of obvious malignant criteria. It is noted whether
the atypical cells are single or in papillary clusters.
Malignant cellspresent
This category consists of specimens that contain cells with unequivocal
criteria of malignancy. If the malignant cells are fewer than ten, the
specimens are designated as 'scanty evidence'
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Figure 1 Photomicrographs of cytological preparations (Papanicolaou stain, xl000). (A) Foam cells, a frequent constituent of NAF; (B) papillary cluster of
benign epithelial cells without atypia; (C) papillary cluster of atypical mammary epithelial cells; (D) malignant epithelial cells
In each case, the entire specimen was cytocentrifuged onto ten
glass slides. Three ofthe slides were used for cytological examina-
tion. If the slides contained less than ten epithelial cells, two addi-
tional slides were examined. The remaining slides (five or seven)
were stored for biomarker studies. The slides selected for cytolog-
ical examination were washed twice in 95% ethanol for5 min each,
rehydrated in tap water and stained by the Papanicolaou method.
Specimen interpretation
The Papanicolaou-stained smears were examined by a cytopathol-
ogist experienced in breast cytology. Each specimen was desig-
nated (Table 1) as containing scant, benign, atypical or malignant
cells, using a classification modified from King et al (1983).
Representative photographs of various types of cells found in
NAF, including benign, atypical and malignant epithelial cells, as
well as foam cells, are illustrated in Figure 1.
Image analysis
Only specimens with adequate cellularity (cytology classes II-IV)
were evaluated by image analysis. Although 88 specimens (53%)
were sufficiently cellular to perform image analysis, this technique
was not employed until more than half of the subjects had been
accrued. Thus far, 48 specimens have been evaluated.
Specimenpreparation
A standardized quantitative DNA staining kit (RIAS Feulgen Stain
Kit, Roche Image Analysis Systems, Elon College, NC, USA) was
used following the manufacturer's instructions. In brief, after
rehydration the slides were processed for hydrolysis with 5 N
hydrochloric acid for 60 min and then transferred to the staining
solution (Schiff's reagent) for 1 h, rinsed, dehydrated and mounted
with synthetic resin.
Specimen interpretation
The Roche Pathology Workstation (Ellison et al, 1995) was used to
evaluate nuclear ploidy, S-phase fraction, percentage of cells in
G2M and percentage hypertetraploid cells (cells with more than
twice their complement of DNA), using computerized image
analysis of cytocentrifuged nipple aspirate epithelial cells stained
with a standard Feulgen preparation. Human lymphocytes were
used as a control diploid cell population. All epithelial cells if
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Table 2 Yield of fluid and epithelial cells by menopausal status
Fluid obtained (%) Cytologya
Status Subjects Attemptsb Cellular Low cellularity No fluid Non-cellular studies only
Overall
Premenopausal 83/86 (97) 221/228 (97) 45 35 3 3
Post-menopausal 84/91 (92) 127/146 (87) 43 37 7 4
Totals 167/177 (94) 348/374 (93) 88 72 10 7
Last 144 subjects
Premenopausal 70/71 (99) 198/200 (98) 38 29 1 3
Post-menopausal 73/73 (100) 107/111 (96) 40 29 0 4
Totals 143/144 (99) 305/311 (98) 78 58 1 7
aCytology: if more than one cytological specimen was collected on a given subject, the most cellular specimen was counted; bAttempts: each subject may have
undergone up to 12 aspiration attempts.
Table 3 Yield of fluid and epithelial cells by breast cancer risk category
Fluid obtained (%) Cytologya
Risk Subjects Attemptsb Cellular Low cellularity No fluid Non-cellular studies only
Normal rsk orfamily history 48/49 (98) 217/220 (99) 19 29 1 0
Personal history of breast cancerc 14/16 (88) 18/30 (84) 3 8 2 3
Precancerous mastopathyc 32/39 (82) 40/51 (75) 22 10 7 0
Invasive cancer 73/73 (100) 73/73 (100) 44 25 0 4
Totals 167/177 (99) 348/374 (95) 88 72 10 7
aCytology: a cellular specimen contains > 10 breast epithelial cells on a slide. If more than one cytology specimen collected on a given subject, the more cellular
specimen was counted; battempts: each subject may have undergone one, two or three aspiration attempts; cpersonal history, precancerous mastopathy: the
nine subjects in whom fluid was not obtained were enrolled very early in the study, before the standardization of our aspiration technique.
Table 4 Cytology in nipple aspirate fluid specimens by risk category
Risk Cytological class
n I 11 Ill IV PLvaluea
Normal risk orfamily history (FH) 50 29 15 6 0
Personal history of breast cancer 10 8 2 0 0 NS
Precancerous mastopathy (PM) 31 10 11 8 2 0.005
Invasive cancer (IC) 69 25 26 11 7 0.004
Overall 0.002
aP-value: NS, not significant; 0.005, PM vs normal risk orfamily history of
breast cancer; 0.004, IC vs normal risk orfamily history of breast cancer;
0.002, overall difference between the groups.
under 100 were present on a slide or a minimum of 100 cells if
more were present were measured per case and type of stain. The
average number ofcells counted per specimen was 30.
Statistical analysis
Cumulative logistic regression models (Agresti, 1990) were fitted
to the data to determine whether the distribution of cytological
groupings was associated with the percentage of cells in G2M,
percentage of cells in S-phase, DNA index, current use of
hormone replacement therapy, current use of oral contraceptives,
previous pregnancy, number oflivebirths, number ofmiscarriages
and whether the subject had difficulty becoming pregnant.
Similarly, these methods were used to determine whether
increasing breast cancer risk categories were associated with cyto-
logical grouping, percentage of hypertetraploid cells, percentage
of cells in G2M, percentage of cells in S-phase and ploidy. The
data did not support the proportional odds assumption for the rela-
tionship between cytological group andpercentage hypertetraploid
cells. Therefore, the Kruskal-Wallis k-sample procedure
(Hollander and Wolfe, 1973) was used to test the null hypothesis
that individuals in the different cytological groups had identical
distributions of hypertetraploid cells in the nipple aspirate fluid.
Failure to reject the null hypothesis (P > 0.05) indicates that
subgroups could not be distinguished. Rejection of the null
hypothesis (P < 0.05) indicates that there are at least two
subgroups where the hypertetraploid values are not identically
distributed.
Fisher's exact two-sided procedures (Agresti, 1990) were used
to determine whether a subject's ability to successfully provide
NAF was associated with menopausal status. Logistic regression
models were fitted to the data using generalized estimating equa-
tions methods (Liang and Zeger, 1986), to determine whether the
menopausal status of the subject was associated with the proba-
bility of successfully obtaining NAF at any given attempt. To
account for any potential within-subject correlation in the outcome
variable, the test statistics were computed using the robust
variance estimates.
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Table 5 Cellular markers in nipple aspirate fluid specimens by cytological class
DNA Index G2M Hypertetraploid cells (%)
Sample
Cytology Size Mean Median Range Mean Median Range Mean Median Range
No atypia 28 1.06 1.03 0.74-1.59 1.61 0 0-6.67 2.14 0 0-26.79
Atypical hyperplasia 14 1.16 1.11 0.98-1.55 2.95 1.14 0-9.8 0.89 0 0-8.6
Malignant 6 1.77 1.78 1.31-2.35 9.20 3.85 0-37.8 17.29 15.79 0-45.16
P-value 0.0002 0.05 0.002
Because image analysis has only recently been employed, 48 specimens have been evaluated in both the DNA index and % hypertetraploid categories.
RESULTS
The correlation of breast cancer risk and NAF cytology with a
variety of clinical factors, including current use of birth control
pills (BCP), current use of hormone replacement therapy (HRT),
whether the subject was ever pregnant, the number of livebirths,
the number of miscarriages, the subject's difficulty becoming
pregnant, the phase ofthe menstrual cycle in which the sample was
obtained and the ease with which NAF was obtained were evalu-
ated. None of these factors correlated with breast cancer risk or
NAFcytology, although the power ofthe analysis ofcurrent use of
birth control pills (BCP) and current use of hormone replacement
therapy (HRT) was diminished by having an unbalanced popula-
tion (few subjects were currently using either BCP or HRT). None
of the clinical factors analysed affected the ability to obtain NAF.
Nor did the interval between aspirations or the number of aspira-
tions affect the ability to obtain fluid or the volume of NAF
obtained on a given visit. Our cytologist did not identify blood in
any NAF sample from women with an intact breast and rarely
found blood in NAF from mastectomy specimens. Using image
analysis, the amount ofDNA in the breast epithelial cells obtained
from NAF and the percentage of cells in each phase of the cell
cycle were also evaluated. Although ploidy, the percentage of
hypertetraploid cells and the percentage ofcells in G2M did corre-
late with NAF cytology, the percentage of cells in the S-phase of
the cell cycle did not.
To evaluate the influence ofmenopausal status on our ability to
obtain NAF, our success in premenopausal vs post-menopausal
subjects was compared (Table 2). The data were presented in two
ways: first as the entire experience with 177 subjects and then with
our most recent 144 subjects, which reflects our success with
nipple aspiration once the technique was standardized. We had
greater overall success per aspiration in pre- vs post-menopausal
subjects (97% vs 87%, P < 0.001), although this difference was not
seen in the last 144 subjects (98% vs 96%, P not significant).
Early in the study, we also assessed the effect ofbreast irradia-
tion on our ability to obtain NAF specimens. Four subjects with
DCIS who underwent prior radiation had theirradiated breast aspi-
rated twice or three times for a total of 11 aspirations. NAF was
obtained only twice and both samples had scant cellularity.
Our success in obtaining both'NAF and cellular specimens in
subjects classified by breast cancerrisk is outlined in Table 3. NAF
was obtained in 167 out of 177 subjects in 348 out of374 attempts.
Fifty-three per cent (88 out of 167) ofthe specimens contained ten
or more breast epithelial cells on a slide, the criterion used to carry
out cellular biomarker determinations.
The correlation of nipple aspirate cytology and image analysis
parameters (DNA index, percentage of hypertetraploid cells, S-
phase fraction, and percentage of cells in G2M) with risk category
was next evaluated (Table 4). Risk was classified as normal risk or
family history of breast cancer, personal history of breast cancer
(prior DCIS or invasive cancer), precancerous mastopathy or inva-
sive cancer. Overall, nipple aspirate cytology (P = 0.002) was
significantly associated with breast cancer risk. Each increased
risk category was compared with normal risk/family history of
breast cancer. Pairwise comparisons revealed that samples from
individuals with invasive cancer (P = 0.004) or precancerous
mastopathy (P = 0.005) were significantly more likely to contain
more abnormal cells.
Cellular markers, including DNA index, percentage of cells in
the S-phase fraction, percentage of cells in G2M of the cell cycle
and the percentage cells with more than twice the normal amount
of DNA (percentage hypertetraploid cells) were evaluated using
image analysis (Tables). DNA index (P = 0.0002), the percentage
of cells in G2M (P = 0.05) and the percentage of hypertetraploid
cells (P = 0.002) increased as cytology became more abnormal
(Figure 2). Although there was a gradual increase in the DNA
index and in the percentage of cells in G2M of the cell cycle that
gradually increased as the cytology became more abnormal, the
pattern seen for cells with hypertetraploidy was slightly different.
In the latter case, the percentage of hypertetraploid cells was
similar for cytological classes II and III, whereas there was a
sudden increase in the number of hypertetraploid cells with class
IV (malignant) cytology.
DISCUSSION
The breast ducts of adult non-pregnant women secrete small
amounts of fluid (Keynes, 1923). This fluid does not escape
because the nipple ducts are occluded by smooth muscle contrac-
tion, dried secretions and keratinized epithelium. Breast fluid can
be obtained by nipple aspiration in a significant proportion of
women without spontanous nipple discharge with the use of a
modified breast pump (Petrakis et al, 1975). This fluid contains
several types of cells, including exfoliated breast epithelial cells
(King et al, 1975). Because breast cancer develops from ductal and
lobularepithelium, NAFis apotentially usefulepidemiological and
clinical research tool. A major limitation ofthe technique has been
the lack ofability to obtain NAF in all women, and when fluid was
obtained it frequently contained few or no breast epithelial cells.
Published data from Petrakis et al (1993) indicate that the
highest yield of NAF is from women aged 30-55 years with early
onset of menarche, non-Asian ethnicity and prior parity and/or
lacation. This procedure has yielded NAF in over 50% of
premenopausal Caucasian and African-American women over
the age of 30. With a definition of > 10 epithelial cells as an
adequate aspiration, others have obtained an adequate specimen in
42% of women aspirated (King et al, 1983). The nipple aspiration
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Figure 2 Box plots of image analysis markers, indicating the median (*), mean (horizontal line within the box), 25-75% confidence intervals (outer box
horizontal lines), and standard deviation (bars above and below the boxes).
(A) DNA index as a function of cytological class; (B) percentage cells in G2M,
as a function of cytological class; (C) percentage hypertetraploid cells, as a
function of cytological class
technique has been employed without significant side-effects in
over 7000 women.
We were able to improve our success in obtaining NAF from
43% at the start of the study to 99% at the present time. Early in
the study, we found that we could often obtain NAF at a second or
third visit, even though NAF was not obtained at the first visit.
This ability to obtain NAF at some but not all visits was not related
to the phase of the menstrual cycle in which the aspiration was
performed. Now we are able to obtain NAF in over 95% of aspira-
tion attempts. In the few subjects who did not yield NAF at the
first visit, we were always able to obtain NAF during subsequent
visits if they were willing to return.
Although Petrakis et al (1993) were more successful in
obtaining NAF in pre- than in post-menopausal subjects, they also
found that age (30-55 years) and ethnicity (non-Asian) were more
important predictors of success in obtaining NAF than menopausal
status. Our interest in the possible influence of menopausal status
on NAF yield led us to determine its importance in our 177
subjects. Although early in our experience we had greater success
(97% vs 87%) in obtaining NAF from premenopausal subjects
(Table 2), menopausal status did not influence our ability to obtain
NAF (98% for pre- vs 96% for post-menopausal subjects) from
our last 144 subjects.
In this report, we demonstrate a higher success rate in obtaining
NAF than has generally been reported (Wrensch et al, 1990). We
attribute this greater success to differences in technique, as well as
to persistence in attempting to obtain NAF. Quite a few modifica-
tions in technique have been made since the first
11 subjects
provided NAF, when the success rate was 43%. We have found
that it is important to warm and massage the breast before aspira-
tion. Allowing the subject to massage her own breast avoids
compression to the point of discomfort. We aspirated each breast
twice at each visit, whereas in most other reports each breast was
aspirated only once. Each subject was asked to return for further
visits. Early in our experience, we examined the NAF cytology in
11 subjects who underwent nipple aspiration two or three times.
The NAF was collected in separate containers at each visit and
cytological review was performed. The cytological classification
of the specimens (Table 1) obtained from the second and third
visit(s) was the same as the first visit in
10 of
11 cases.
We felt that it was important to study subjects of a single risk
category (precancerous mastopathy) when we were assessing the
feasibility ofthe procedure. Thus, the first 33 subjects recruited all
had a diagnosis of DCIS, LCIS or AH. Early into this pilot study
we realized, however, that only the untreated breast in subjects
with a history of DCIS could be aspirated. Thus, the pilot included
subjects now classified as having either precancerous mastopathy
or a personal history of breast cancer. Nine of the ten subjects in
whom nipple aspiration was unsuccessful were enrolled during the
pilot study. We later broadened our entry criteria to include
subjects of all risk categories. Since we have standardized our
aspiration technique, we have been equally successful in obtaining
NAF from subjects of all risk categories.
Wrensch et al (1993) evaluated NAF in a cohort of subjects with
normal breast cancer risk. In this population, they demonstrated
that subjects with NAF that contained normal cytology, hyper-
plasia without atypia, or atypical hyperplasia have a risk of breast
cancer similar to subjects who have a biopsy with similar diag-
noses. They also reported that subjects with scant cellularity had
the lowest risk. Our goal was to determine the usefulness of NAF
cytology in subjects of all risk categories. We therefore evaluated
NAF in women of each risk category, and correlated the cytolog-
ical findings with breast cancer risk, based on family history or
prior pathology. NAF cytology was highly coffelated (P = 0.002,
Table 4) with breast cancer risk, suggesting that cytology may be a
useful biomarker for subjects of various risk categories.
Ca re r C pg 9British Journal of Cancer (1997) 76(4), 494-501
--T-
0
0
0 CancerResearch Campaign 1997500 ER Sauteretal
Computerized image analysis is able to quantitate the DNA
index and cell cycle parameters on a cell by cell basis. The prog-
nostic utility of this modality has been demonstrated for a variety
of tumours, including breast cancer (Dressler et al, 1988).
Although flow cytometry is the standard method to determine
cellular DNA, image analysis using Feulgen-stained cell prepara-
tions is gaining wider acceptance because of its ability to evaluate
samples of relatively scant cellularity. Moreover, studies have
demonstrated agood correlation between DNA indices determined
by flow and image cytometry (Ellison et al, 1995).
DNA indices in epithelial cells from nipple aspirate specimens
were determined and evaluated for their correlation with cytolog-
ical class. Increasing DNA index, increasing percentage ofcells in
G2M and increasing percentage of hypertetraploid cells were
found as the cytology became more abnormal, suggesting their
potential usefulness as biomarkers.
The correlation between cytology and risk (Table 4) may under-
estimate the true significance of the relationship because of the
way in which the NAF samples were collected. Over 90% of the
NAF specimens with recently diagnosed DCIS or invasive breast
cancer came from a mastectomy specimen. Thus, only one aspira-
tion attempt was possible. On the other hand, the majority of
women with a normal breast cancer risk or a family history of
breast cancer agreed to undergo multiple aspirations, some as
many as 12. One would expect that increasing the number of
samples would increase the chance of finding abnormal cells
should they exist. Ofthe 13 subjects with normal breast cancer risk
who underwent aspiration 1-6 times, no cytology specimen
contained atypical cells. Of the nine subjects at normal risk who
underwent aspiration 12 times, two (22%) had atypical hyperplasia
(AH). The study by Wrench et al (1993) would suggest that the
subjects thought to be at normal risk, with NAF cytology demon-
strating AH, have a risk of breast cancer similar to if they had
undergone a biopsy demonstrating atypical hyperplasia. In the two
subjects with AH found in NAF; who were presumed to have
normal breastcancerrisk, NAF was useful in identifying that these
women were at increased risk. Although a statistical correlation
was not found between cytological class and the number of aspira-
tions, it is logical that increasing the number of aspirations will
increase the likelihood of finding abnormal cells. In order to
increase the likelihood of finding abnormal cells, NAF may be
most useful when performed more than once or at intervals, as are
breast examinations or mammograms.
All NAF samples that are fixed and prepared properly are evalu-
able for cytology, for even a cytological classification of I (inade-
quate cells) provides important prognostic information. [Subjects
with class I cytology seem to have the lowest breast cancer risk
(Wrensch et al, 1993).] As indicated in Table 3, we elected to use
the entire sample from seven subjects for non-cellular studies,
because of our interest in certain non-cellular markers. One of the
markers, prostate-specific antigen (PSA), has proven to be a very
promising marker of breast cancer risk (Sauter et al, 1996). Non-
cellular markers in NAF are in theory always evaluable, so long as
the protein ofinterest can be detected. In our hands, 1 gl ofNAF is
more than sufficient to detect and quantify PSA.
On the other hand, we are presently able to obtain samples of
adequate cellularity for DNA ploidy and cell cycle determinations
in just over 50% of subjects. Although we do not know if we can
increase the percentage of subjects providing cellular samples, we
feel that we can increase the quantity of breast epithelial cells
obtained from subjects who do provide cellular samples. The
quantity of cells obtained is important, as a large number of cells
are required for a variety of tests (e.g. proliferation score). At
present, we are performing two aspirations on each breast at each
visit. It is our impression that two aspirations on each breast do not
remove all of the fluid from the breast. A simple method, then, to
increase the number of breast epithelial cells obtained would be to
perform a third aspiration on each breast at each visit. We feel that
a third aspiration would be well tolerated, as the procedure is quick
and causes minimal to no discomfort. Nonetheless, because not all
of the specimens will contain sufficient cells for evaluation, we
believe that non-cellular (e.g. PSA) as well as cellular markers of
breast cancer risk should be used in combination to maximize the
information obtained from the NAF sample.
We do not plan to perform nipple aspiration in a previously irra-
diated breast. The low yield of both NAF and cellular specimens
indicates that radiation treatment significantly alters the
secretion of both fluid and cells into the breast ductal lumen. We
have elected not to aspirate individuals who have received
chemotherapy for any malignancy because ofthe possible effect of
this treatment on the aspiration specimen.
We can envisage two possible uses for the nipple aspirate fluid:
one as an adjunct to screening and a second to evaluate inter-
mediate markers for change in response to a chemopreventive
agent. A subject coming in for her annual examination by her
gynaecologist or family physician could undergo nipple aspiration
eitherjust before orjust after the physical examination. The aspira-
tion need not be done by a physician, so long as the individual is
properly trained to perform the procedure. The aspiration takes
only 5-10 min to perform, and can be repeated as early as 3 days
later if more fluid is needed (probably even sooner, although we
have not tested this). One or more of the capillary tubes containing
NAF could be sent to a reference laboratory for analysis of one or
more non-cellular markers, such as PSA. A second capillary tube
containing NAF could be emptied into a cytological fixative, and
sent to a cytologist with expertise in reading aspirates from body
cavities, breast cysts, cerebrospinal fluid, etc. One microlitre is
usually sufficient for both non-cellular and cellular studies,
although a larger quantity is helpful. In the ideal scenario, if the
technique were to become widely accepted, a buffer for the non-
cellular marker(s) and the cytological fixative for whole-cell
studies, such as cytology and DNA image analysis, contained in a
commercially available kit would streamline and standardize the
testing ofNAF. Even without this 'kit', however, the preparation of
the sample for analysis is extremely simple, requiring only that one
flush the NAF sample into the buffer or fixative with a 21-gauge
needle. A similar approach to the collection of and preparation of
NAF could be performed in subjects participating in a chemopre-
vention trial, in which the investigator would monitor the
biomarker(s) ofinterest for changes from abnormal towards a more
normal phenotype.
In summary, nipple aspiration is a feasible method to obtain
breast epithelial cells in non-lactating women. The procedure is
inexpensive, quick, non-invasive, can be repeated as needed and
causes minimal to no discomfort. It is extremely successful in
young women, for whom mammography is often non-revealing
because of the density of the breast tissue. Despite its limitations,
nipple aspiration has the potential to supplement mammography
and physical examination in women who yield evaluable fluid.
Given that both cytology and DNA indices are promising inter-
mediate biomarkers, as well as the identification ofpromising non-
cellular markers such as PSA, nipple aspiration may be a useful
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tool to evaluate response to treatment with a chemopreventive
drug. These markers could best be validated in a randomized,
prospective trial.
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